We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
ZEPOSIA (Celgene Pty Ltd)
Product name
ZEPOSIA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
ozanimod hydrochloride
Registration type
NCE/NBE
Indication
ZEPOSIA (capsule) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis.